

Response to Restriction Requirement dated June 30, 2006  
U.S. Patent Application No. 10/672,144  
Attorney Docket No. 13664.105037

**REMARKS**

In the Election/Restriction Requirement mailed June 30, 2006, the Examiner required restriction of the above-identified patent application to "a single combination of the biologically active factors to which the claimed combination comprises." In response to the Election/Restriction Requirement mailed June 30, 2006, Applicants elect Tumor Necrosis Factor Alpha ("TNF- $\alpha$ ") and Interleukin-12 ("IL-12") as a single combination of the biologically active factors, which read upon at least Claims 27-35.

Response to Restriction Requirement dated June 30, 2006  
U.S. Patent Application No. 10/672,144  
Attorney Docket No. 13664.105037


**CONCLUSION**

Applicants submit the foregoing as a full and complete response to the Restriction Requirement mailed on June 30, 2006. The Applicants and the undersigned thank Examiner Angell for considering these remarks.

If any issues exist that can be resolved with an Examiner's Amendment or a telephone conference, please contact Applicants' undersigned attorney at (404) 572-2778.

Other than the five-month extension fee, no additional fees are believed to be due in connection with this response. However, should the Commissioner determine otherwise, he is authorized to charge such fees and credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

  
Richard J. Pearson, Jr., Ph.D.  
Reg. No. 59,843

KING & SPALDING LLP  
1180 Peachtree Street, N.E.  
Atlanta, Georgia 30309-3521  
Phone: (404) 572-2778  
Fax: (404) 572-5135

Date: January 3, 2007

4368689

Page 3 of 3

PAGE 7/7 \* RCVD AT 1/3/2007 11:12:07 AM [Eastern Standard Time] \* SVR:USPTO-EFAXF-5/11 \* DNIS:2738300 \* CSID:404 572 5134 \* DURATION (mm-ss):02-08 16F.07 \*\*

**BEST AVAILABLE COPY**